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Abstract 
Addictive drugs enhance dopamine release in the striatum, which can lead to compulsive drug-
seeking after repeated exposure. Glial cell line-derived neurotrophic factor (GDNF) is an important 
regulator of midbrain dopamine neurons, and may play a mechanistic role in addiction-related 
behaviors. To elucidate the components of GDNF-signaling that contribute to addiction-related 
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behaviors of place preference and its extinction, we utilized two genetically modified GDNF mouse 
models in an amphetamine-induced conditioned place preference (CPP) paradigm and evaluated 
how the behavioral findings correlate with dopamine signaling in the dorsal and ventral striatum. 
We utilized two knock-in mouse strains to delineate contributions of GDNF and Ret signaling using 
MEN2B mice (constitutively active GDNF receptor Ret), and GDNF hypermorphic mice (enhanced 
endogenous GDNF expression). The duration of amphetamine-induced CPP was greatly enhanced 
in MEN2B mice, but not in the GDNF hypermorphic mice. The enhanced duration of CPP was 
correlated with increased tyrosine hydroxylase (TH) expression and dopamine content in the 
ventral striatum. Together, our results suggest that downstream components of GDNF signaling, in 
this case Ret, may mediate persistent drug-seeking behavior through increased TH expression and 
dopamine levels in the mesolimbic dopamine neurons. 
Highlights: 
 Constitutive Ret signaling causes long-lasting amphetamine-induced place preference 
 Moderate GDNF increase does not alter amphetamine-induced place conditioning 
 Long-lasting place preference correlates with increased mesolimbic dopamine 
 GDNF signalling via Ret mediates drug-seeking through increased mesolimbic dopamine 
Keywords: amphetamine; conditioned place preference; dopamine; GDNF; MEN2B; striatum  
Abbreviations: CPP, conditioned place preference; DOPAC, 3,4-dihydroxyphenylacetic acid; dSTR, 
Dorsal striatum; GDNF, Glial cell line-derived neurotrophic factor; HVA, Homovanillic acid; MEN2B, 
Multiple endocrine neoplasia type 2 B; PFC, prefrontal cortex; Ret, Rearranged during transfection 
SN, Substantia nigra; TH, Tyrosine hydroxylase; vSTR, Ventral striatum; VTA, Ventral tegmental 
area.  
1. Introduction 
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Striatal dopamine plays a key role in behavioral reinforcement and reward signaling. Stimulants 
can increase dopamine release in the striatum, and consequently dissociate these learning 
mechanisms from their normal drive by environmental cues (reviewed by Sulzer, 2011). After a 
critical number of exposures, behaviors aiming for acquisition of these reinforcing drugs eventually 
become highly compulsive and manifest as drug addiction (Camí and Farré, 2003; Volkow et al., 
2016). Environmental stimuli previously associated with drug use (cues) play a major role to 
induce a conditioned response (craving and relapse), even in the absence of the drug and after 
long periods of abstinence (Camí and Farré, 2003; Stolerman, 1992). Hence, the dopaminergic 
associative learning mechanisms are the key drivers in the development and maintenance of 
addiction-related behavior. 
Ectopically applied Glial cell line-derived neurotrophic factor (GDNF) provides trophic support for 
midbrain dopaminergic neuron functions, both in vitro (Burke et al., 1998; Lin et al., 1993) and in 
vivo (Beck et al., 1995; Hoffer et al., 1994). Perhaps a lesser known aspect of GDNF signaling is the 
role it may play in the behavioral effects of addictive drugs (Carnicella and Ron, 2009; Messer et 
al., 2000), which also carries a significant dopaminergic component from the mesolimbic pathway. 
Nevertheless, the role of GDNF in addiction has remained unclear, as there is evidence to support 
that GDNF signaling promotes or inhibits addiction processes (reviewed by Ghitza et al., 2010; 
Koskela et al., 2017). This ambiguity is at least in part due to shortcomings in the approaches used 
to evaluate the role of GDNF signaling in addiction. For example, the use of ectopic GDNF or 
GDNF-neutralizing antibodies to evaluate the role of GDNF in addiction may not represent the 
physiological context of GDNF signaling in an addiction process (Ghitza et al., 2010; Koskela et al., 
2017). Furthermore, the use of  heterozygous mice lacking one functional GDNF allele could 
trigger compensatory mechanisms that mask or interfere with the phenotype (Ghitza et al., 2010; 
Routtenberg and Gerlai, 1996). 
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To further delineate the contribution of GDNF-signaling in the addiction process, we utilized two 
knock-in mouse models, both of which increase two components of endogenous GDNF signaling. 
In multiple endocrine neoplasia type 2B (MEN2B) mice, GDNF’s main signaling receptor Ret 
(Rearranged during transfection) is constitutively active as a result of a single point mutation 
(Mijatovic et al., 2007; Smith-Hicks et al., 2000). In GDNF hypermorphic mice (Gdnfwt/hyper), 
endogenous GDNF expression from one Gdnf allele is enhanced due to increased mRNA stability, 
which doubles endogenous striatal levels of GDNF (Kumar et al., 2015). In the present study, we 
investigated the behavioral responses of these animal models in amphetamine-induced 
conditioned place preference (CPP) paradigm, where the rewarding properties of amphetamine 
are associated with environmental cues via repeated exposures. This conditioning phase causes 
animals to shift their preference towards the amphetamine-paired environment, when given a 
free choice (Cunningham et al., 2006). In addition, we investigated dopamine levels and 
metabolism in the nigrostriatal and mesocorticolimbic brain areas of these mice to determine 
whether indices of dopamine biosynthesis (tyrosine hydroxylase expression and phosphorylation) 
mediate GDNF signaling-related mechanisms associated with the behavioral phenotypes. We 
found that in MEN2B mice the duration of amphetamine-induced place conditioning was greatly 
enhanced and endured long after it was extinguished in the wild-type, whereas the Gdnfwt/hyper 
mice did not differ from their wild-type littermates in CPP paradigm. The enhanced CPP duration 
in MEN2B mice was correlated with increased levels of dopamine and tyrosine hydroxylase (TH) 
specifically in the ventral compartment of the striatum.  
2. Material and methods 
2.1. Animals 
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The generation and genotyping of MEN2B and GDNF hypermorphic knock-in mice has been 
previously described (Smith-Hicks et al., 2000; Kumar et al., 2015). The mice were bred in the 
animal facility at the University of Helsinki. MEN2B mice maintained in 129Ola/C57BL6 mixed 
background (Mijatovic et al., 2011) were first crossed to ICR strain and then several times to wild 
type mice from the GDNF hypermorphic colony in order to bring them to the same triple-mixed 
genetic background as the GDNF hypermorphic strain (129Ola/ICR/C57BL6). Male mice and 
littermate controls were used at 8–14 weeks of age. The mice were housed under temperature-
controlled conditions at 20–22°C in a 12h/12h light/dark cycle. Each cage contained 2–6 animals, 
and the mice had ad libitum access to standard chow and water. Animal experiments were 
conducted according the 3R principles of the EU directive 2010/63/EU governing the care and use 
of experimental animals, and following local laws and regulations [Finnish Act on the Protection of 
Animals Used for Scientific or Educational Purposes (497/2013, Government Decree on the 
Protection of Animals Used for Scientific or Educational Purposes (564/2013)]. The protocols were 
authorized by the national Animal Experiment Board of Finland. 
2.2. Amphetamine-induced place conditioning 
For the behavioral experiments both MEN2B and GDNF hypermorphic strains were backcrossed 
once to C57BL6 strain. As we only had six homozygous MEN2B (M2B/M2B) mice for the behavioral 
experiments, they were all conditioned to the same side (Grid+). As the behavioral data from 
these M2B/M2B mice was completely homogenous with Wt/M2B data, we combined the groups 
into a common M2B group. However, as this disrupts the counterbalancing within the M2B group, 
we have also presented the CPP data without the M2B/M2B mice in the Figure S1A–K. Cages were 
changed once per week after the behavioral session of that day was completed. One week before 
the experiments all animals were systematically handled every day for five days to minimize 
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experimenter-related stress during the experiment. Over the days the mice gradually received 
more active and intensive handling, where they were standing on a hand, lifted out of their cage 
and briefly immobilized to a similar grip where they would later receive injections. 
CPP experiments were conducted in rectangular chamber with place preference inserts (activity 
monitor; MED Associates, St Albans, GA, USA). The chamber was divided into two compartments 
(21 x 42 x 41 cm3) that had different tactile cues and were separated by a black wall with a 
guillotine door. One compartment had a metal grid floor (Grid), while the other had perforated 
grey plastic floor with 7.5 mm holes 16 mm apart (Hole). Movement and location of the animals 
were recorded with infrared photobeam interruptions. Before the experiments all chambers were 
washed with water and soap, but during the experiment only visible excrements were removed 
after each session. Before the first experimental session male mice that were not part of the 
experiment were placed to the chambers for 30 minutes to attach mouse smell into the 
apparatus. White noise was used during the experiments to cover background noises.  
We used an unbiased and counterbalanced experimental design (Cunningham et al., 2006), where 
half of the animals in each genotype were randomly assigned to receive amphetamine in one 
compartment and vehicle (0.9 % saline) in the other. Hence, half of the animals in each genotype 
were assigned to the Grid+ conditioning subgroup (Grid + amphetamine, Hole + saline) and half of 
them to the Grid– conditioning subgroup (Hole + amphetamine, Grid + saline). Amphetamine 
induced CPP is defined as a significant difference between the Grid+ and Grid– subgroups in an 
analysis of time spent on the grid floor (Cunningham et al., 2006, 2003). As the subgroups are 
matched for exposure to amphetamine, saline and each of the floor stimuli, the differences 
between the subgroups can be attributed to differences in learning about the paired relationship 
between the floor and the drug effects (Cunningham et al., 2006, 2003). Time spent on the grid 
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floor is expressed as mean seconds per minute during the 15 minutes test session as reported by 
(Cunningham et al., 2006). The CPP trial was divided into 5 phases: (1) habituation, (2) 
conditioning, (3) preference test, (4) extinction and (5) reinstatement. From habituation until 
preference test the procedure was conducted five days per week with a 2-day weekend break. 
The habituation phase took place 24 hours before the first conditioning and did not involve any 
injections. The animals were placed to the CPP chamber for 15 minutes with the guillotine door 
open, so they could freely explore both compartments. Time spent in each compartment and 
locomotor activity were measured. 
In the conditioning phase, mice received a total of four injections of amphetamine (2 mg/kg, i.p., 
in 0.9 % saline; Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, 
University of Helsinki, Finland) and four injections of saline on alternating days. The groups were 
counterbalanced for the order in which they received each treatment (amphetamine or saline 
first). There was a 24 h delay between successive conditioning trials that took place at the same 
time of the day for each animal. The animals were placed into the CPP chambers immediately 
after receiving the injections for 30 minutes recording with the guillotine door closed. 
The preference test was carried out 24 h after the final conditioning session to measure whether 
the animals had developed place preference to the drug-paired compartment. The preference test 
was identical to the habituation session. The extinction phase started 72 h after the preference 
test and took place three times per week with one or two days between the sessions. The 
extinction session was otherwise similar to habituation and preference test, except that the 
animals stayed in the chamber for 30 minutes, which speeds up the reversal learning (Cunningham 
et al., 1998). However, they were only recorded during the first 15 minutes. 
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Finally, reinstatement took place 24 h after the final extinction session. The reinstatement trial 
was similar to the extinction, but the animals received a small challenge dose of amphetamine (0.5 
mg/kg, i.p.) prior being placed to the CPP box for 30 minutes recording. 
2.3. Brain dissection 
For brain monoamine measurements and western blot analysis samples were obtained from the 
relevant dissected brain regions of drug-naïve animals using a mouse brain matrix as previously 
described (Kopra et al., 2017). In addition, prefrontal cortex (PFC) was collected from in front of 
the striatal slice after removal of the olfactory bulbs. 
2.4. Estimation of monoamines and their metabolites 
Dopamine and its metabolites were analyzed from the dissected brain samples as described 
previously (Valros et al., 2015) using HPLC with electrochemical detection. The values of 
monoamines and their metabolites are presented as nanograms per gram of wet tissue weight. 
2.5. Western blot analysis 
The remaining tissue pellet from HPLC sample preparation was re-dissolved and homogenized by 
ultrasound in 5 mM Tris buffer (pH 8.3) containing 1 mM EDTA and 1 % SDS previously described 
(Salvatore et al., 2012). Next, the samples were boiled at 97 °C for 5 min and protein 
concentration was measured using BCA assay (Thermo Scientific, Rockford, IL, USA). Western blot 
samples containing 20 µg (for TH) or 5–10 µg (for pSer31 TH) of total protein were prepared in 4x 
Laemmli buffer (Bio-Rad, Hercules, CA, USA). In case the sample turned yellow after Laemmli 
buffer addition, 1 M Tris (pH 8.2) was added in 5 µl increments until blue color was restored. 
Samples were loaded onto Stain-Free 4–20 % gels (Bio-Rad). Calibrated standards for TH or pSer31 
TH protein (Salvatore and Pruett, 2012) were prepared in mouse liver homogenate and loaded 
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onto gels along with the samples to create standard curves. Gel run was performed at 200 V for 30 
min and transferred onto Trans-Blot Turbo 0.2 µm nitrocellulose membranes (Bio-Rad). The 
protein loads were normalized using Ponceau S staining as previously described (Salvatore et al., 
2012). Then, the membranes were blocked 1 hour in 5 % skim milk in TBS containing 0.5 % 
Tween20 (T-TBS), followed by primary antibody (TH; rabbit-anti-TH, 1:1000; AB 152, Millipore, 
Temecula, CA, USA, or pSer31 TH 1:300 (Salvatore et al., 2009b); 21st Century Biochemicals, 
Boston, MA, USA) incubation at 4 °C overnight. After 2 hour secondary antibody incubation (Goat 
anti-rabbit-HRP Conjugated; 1:2000, 170-6515, Bio-Rad), signal was detected using Li-Cor C-Digit 
blot scanner (Lincoln, NE, USA) and band optical densities were analyzed with Image Studio 
software (Li-Cor). TH or pSer31 TH protein amounts in the tissue samples were calculated based 
on the standard curves. 
2.6. Statistical analyses 
Data from more than two groups (MEN2B, three genotypes) were analyzed using a one-way 
ANOVA, which was followed by the Student-Newman-Keuls post hoc analysis in the case of a 
significant ANOVA result. Statistical analysis for pairwise comparisons was performed using 
Student’s t-test with two-tailed distribution and the equal variance option. In the CPP experiments 
a significant difference between Grid+ and Grid– subgroups provides evidence of place 
conditioning (Cunningham et al., 2006), so statistical comparisons were made between the means 
of these subgroups using Student’s t-test with two-tailed distribution and the equal variance 
option. A three-way ANOVA for repeated measures [genotype x treatment x time (days 1-4) as 
factors] was used to analyze locomotion data. All summary data are reported as the mean ± the 
standard error of the mean (SEM). 
3. Results 
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3.1. Expression of place preference in MEN2B mice 
During the conditioning sessions, MEN2B mice displayed greater amphetamine-induced locomotor 
activation compared to their wild-type littermates, but not after saline injections (Figure 1A). This 
difference was also seen in the reinstatement trial (Figure 1B). The activity of MEN2B mice was 
similar to their controls during habituation phase and in the preference and extinction tests 
(Figure 1B). The mice did not display strong preference to either side of the CPP chamber (54 % of 
time spent on grid) during the habituation phase indicating that the system was unbiased (Figure 
1C). 
The four conditioning sessions with amphetamine resulted in place preference both in MEN2B and 
their wildtype littermates indicated by a significant difference in the time spent on the grid floor 
between the two conditioning subgroups [amphetamine on grid (Grid+) or amphetamine on 
plastic floor (Grid-)] (Figure 1D).  
We next evaluated the longevity of CPP expression. The wild-type controls did not display CPP 
beginning with the second extinction trial (Figure 1E–F). However, in the MEN2B mice, CPP was 
still present at the 12th extinction test (Figure 1E–L). The total duration of CPP in the MEN2B mice 
lasted out to at least 36 days, being five times longer duration than in the wild-types (Figure 1L). 
The priming dose of amphetamine (0.5 mg/kg) induced reinstatement of place preference in both 
groups, as indicated by a significant difference in the time spent on the grid floor between the two 
conditioning subgroups (Figure 1M). 
In conclusion, MEN2B mice displayed an enhanced locomotor response to amphetamine and 
persistent expression of amphetamine-induced place preference. The MEN2B mutation did not 
affect the magnitude of place preference displayed in the preference test or the amphetamine-
induced reinstatement of drug seeking. 
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3.2. Expression of place preference in GDNF hypermorphic mice 
During the conditioning phase, neither saline- or amphetamine-induced locomotor activity was 
significantly increased in Gdnfwt/hyper mice compared to the controls (Figure 2A). However, both 
genotypes displayed similar and clear locomotor sensitization to the repeated amphetamine 
injections (Figure 2A). There were no differences in locomotor activity between the genotypes 
either during the habituation, preference, extinction or reinstatement tests (Figure 2B). The mice 
displayed a mild preference to the grid side (61 % of time spent on grid) during the habituation 
phase indicating that the system was very close to being unbiased (Figure 2C). 
The four pairings with amphetamine during the conditioning resulted in a similar CPP in both 
genotypes (Figure 2D). However, both genotypes no longer displayed CPP in the first extinction 
trial (Figure 2E) and this behavioral phenotype continued for the duration of the extinction phase 
of the experiment (Figure 2F–I). 
The priming dose of amphetamine (0.5 mg/kg) induced reinstatement of CPP, where both 
genotypes showed a significant difference in the time spent on the grid floor (Figure 2J). 
Taken together, amphetamine-induced locomotor activity and CPP, and its extinction, in 
Gdnfwt/hyper mice were not different from their wild-type littermates. 
3.3. Increased dopamine and tyrosine hydroxylase expression in both striatal compartments of 
MEN2B mice 
To elucidate possible mechanisms underlying the differences in CPP duration between the MEN2B 
and Gdnfwt/hyper mice, we measured the levels of dopamine and its metabolites 
dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the dorsal striatum (dSTR), 
ventral striatum (vSTR), prefrontal cortex (PFC), substantia nigra (SN) and ventral tegmental area 
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(VTA) of drug-naïve animals. The levels of TH protein and serine 31 phosphorylated form of TH 
(pSer31 TH) were determined in the same dSTR and vSTR samples assessed for dopamine and 
metabolites (Salvatore et al., 2012). In MEN2B mice there was increased tissue dopamine (~25 % 
for Wt/M2B, ~40 % for M2B/M2B) and DOPAC (~40 % for Wt/M2B, ~100 % for M2B/M2B) in dSTR 
(Figure 3A–B), whereas HVA levels were unchanged (Figure 3C). There were parallel increases in 
TH and pSer31 TH levels, but no difference in the pSer31 TH levels/total TH ratio in dSTR (Figure 
3D–F, see presentative bands in Figure S4), indicating that ser31 phosphorylation was unaffected. 
In vSTR, dopamine was also increased, and to a greater extent than in dSTR, being ~50 % for 
Wt/M2B and ~70 % for M2B/M2B. DOPAC was also increased (~80 % for Wt/M2B, ~160 % for 
M2B/M2B) (Figure 3G–H), as well as HVA levels (~240 % for M2B/M2B) (Figure 3I). Similar to the 
dSTR, there were parallel increases in TH and pSer31 TH levels, but no difference in the pSer31 TH 
levels/total TH ratio in vSTR (Figure 3J–K). Generally, in both striatal compartments the elevations 
in dopamine and TH tended to be higher in homozygous (M2B/M2B) than in heterozygous 
(M2B/Wt) animals, even though this difference did not always reach statistical significance. In 
MEN2B PFC dopamine and HVA levels were unchanged, but DOPAC levels were slightly increased 
in homozygous animals (Figure S2A–C). In SN dopamine and DOPAC were elevated, but HVA 
remained unchanged (Figure S2D–F). Finally, in the VTA dopamine levels were increased, while 
DOPAC and HVA were unchanged (Figure S2G–I). 
In conclusion, there were very robust and gene dose-dependent increases in the levels of 
dopamine as well as its primary metabolite DOPAC and expression of TH in both dorsal and ventral 
striatal compartments of MEN2B mice. In the other dopaminergic brain areas, there were also 
some similar, but less robust, increases in dopamine and metabolite levels. Generally, the relative 
elevations in dopamine, DOPAC and HVA in MEN2B tended to be up to two times greater in the 
mesolimbic (vSTR and VTA) than in the nigrostriatal (dSTR and SN) tract. 
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3.4. In GDNF hypermorphic mice dopamine levels are unchanged in ventral striatum 
Gdnfwt/hyper mice also have elevated levels of dopamine (~25 %) and DOPAC (~45 %) in dSTR 
(Kumar et al., 2015). However, we did not observe any differences in TH or pSer31 TH levels or in 
the pSer31 TH/total TH ratio in the same samples (Figure 4A–C). In contrast, in the vSTR of the 
same animals, dopamine, DOPAC and HVA levels were unchanged (Figure 4D–F). Moreover, in 
vSTR there were no differences in TH or pSer31 TH levels, although there was a small, but 
significant reduction in the pSer31 TH/total TH ratio (Figure 4G–I). This is in contrast to TH 
expression and dopamine content seen in MEN2B mice, where both were increased in the vSTR. 
There were no significant differences in dopamine, DOPAC or HVA levels in PFC (Figure S3A–C) or 
SN (Figure S3D–F) in Gdnfwt/hyper mice, while only dopamine levels were slightly elevated in the 
VTA (Figure S3G–I). 
Taken together, the dopaminergic phenotype in Gdnfwt/hyper mice appears to be primarily limited 
to the dSTR. Furthermore, the lack of difference in TH expression and dopamine in the vSTR of the 
Gdnfwt/hyper mice, in contrast to these differences observed in the MEN2B mice, may be the 
mechanistic basis to explain why Gdnfwt/hyper mice do not differ from their littermate controls in 
the duration of amphetamine-induced CPP. 
4. Discussion 
Altered dopamine neurotransmission within the mesocorticolimbic system mediates the 
components of drug reward (Pierce and Kumaresan, 2006) and relapse to drug-seeking (Shalev et 
al., 2002). Mesocorticolimbic dopamine system consists of dopaminergic cell bodies in the VTA 
that project to several brain areas including PFC, vSTR and amygdala (Fallon and Moore, 1978; 
Ungerstedt, 1971). Compulsive drug-seeking and long-term vulnerability to relapse result from 
drug-induced neuroadaptations in the mesocorticolimbic dopamine system and the glutamatergic 
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circuitry that is modulated by the VTA dopaminergic projections. Our present results suggest that 
alterations in the function of the GDNF signaling receptor Ret may mediate persistent drug-
seeking behavior in association with increased TH expression in the mesolimbic dopaminergic 
neurons. MEN2B mice, with constitutively active Ret, developed highly persistent amphetamine-
induced place preference, notably with increased TH expression and dopamine in vSTR. In 
contrast, CPP expression in the Gdnfwt/hyper mice with unchanged vSTR dopamine and TH levels did 
not differ from their wild-type littermates in the same trial. 
Amphetamine is a widely abused drug that increases extracellular dopamine levels in the striatum 
(Ungerstedt and Pycock, 1974). Amphetamine is taken up to the nerve terminals by the dopamine 
transporter (DAT), where it releases dopamine from the synaptic vesicles leading to its DAT-
mediated outflow to the extracellular space (Reviewed by Sulzer, 2011). Administration of 
amphetamine causes euphoria and alertness as well as increased arousal, concentration and 
locomotor activity (Camí and Farré, 2003). As amphetamine releases existing dopamine from the 
vesicles, it is likely that the higher striatal dopamine levels in MEN2B mice caused them to respond 
stronger to amphetamine. This was evidenced by increased locomotor activity after amphetamine 
injections and by much longer expression of amphetamine-induced CPP compared to their wild-
type littermates. The amphetamine-related increase in extracellular dopamine levels in vSTR of 
MEN2B mice may result in more persistent neuroadaptations in neurocircuits involved in 
associative learning and behavioral reinforcement. Indeed, we have previously shown that MEN2B 
mice have increased dopamine uptake and release in the dSTR (Mijatovic et al., 2008). Striatal 
dopamine regulates long-term changes in synaptic strength via long-term potentiation (LTP) and 
depression (LTD) (Gerfen and Surmeier, 2011). Most likely these are the key neuronal mechanisms 
in MEN2B vSTR that underlie the persistent behavioral alterations. Finally, since 30 injection days 
of amphetamine with up to 20 mg/kg per day does not affect striatal tissue dopamine levels 
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(Robinson and Camp, 1987), we felt safe to assume that the low amphetamine dose of 2 mg/kg for 
4 days in this study does not alter striatal tissue dopamine levels. Future studies are needed to 
share further light into how MEN2B mutation manifests its effects. 
To our surprise, and unlike in the regular open field test (Kumar et al., 2015), Gdnfwt/hyper mice did 
not run significantly more than their wild-type littermates after receiving amphetamine in the CPP 
trial. This might be due to interference from the CPP chamber and floor cues, the higher 
amphetamine dose used (2 mg/kg versus 1 mg/kg) or the shorter follow-up time (30 min versus 60 
min). Nevertheless, enhanced dopamine content in the dSTR did not alter CPP in these mice, which 
suggests that the vSTR dopamine plays a key role in this test. Overall, our results suggest that a 
moderate increase in endogenous GDNF levels does not predispose to an increased risk to develop 
addiction. 
Both mouse lines used in this study are constitutive knock-in mutants, which means that Gdnf and 
Ret genes are mutated in their native loci thereby avoiding artefacts associated with transgenic 
overexpression via random integration or viral expression. However, knock-in mice  carry their 
mutant alleles throughout development and maturation (Kumar et al., 2015; Smith-Hicks et al., 
2000). The important question in the future is to dissect whether the observed phenotype in 
MEN2B is caused by the effects on the development or on neurotransmission and neuroplasticity 
in the adult animals or a combination of the two. Another important question is why dopamine 
and TH levels (and the resulting amphetamine CPP) were changed in MEN2B mice, but unaltered 
in Gdnfwt/hyper mice. Our hypothesis is that this is at least in part because in the adult Gdnfwt/hyper 
mice, Gdnf expression is significantly increased only in the dorsal, not in the ventral striatum 
(Kumar et al., 2015). Perhaps more importantly, due to activating mutation Ret is constitutively 
active in MEN2B mice and unresponsive to physiological regulation of GDNF levels (Smith-Hicks et 
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al., 2000), while in Gdnfwt/hyper mice the wild-type Ret context allows on-off signaling events in 
response to ligand levels. At this stage, we cannot discriminate between these two options. 
However, we believe that the lack of significant GDNF increase in adult vSTR of Gdnfwt/hyper mice is 
the most likely explanation. 
Previous studies have reported that heterozygous GDNF knockout (Gdnfwt/KO) mice are more 
sensitive to cocaine- and methamphetamine-induced CPP (Messer et al., 2000; Niwa et al., 2007) 
and they also self-administer more methamphetamine (Yan et al., 2007). This contrasts with our 
present study, where increased GDNF signaling did not protect the animals from amphetamine-
induced CPP. In fact, CPP was unchanged in Gdnfwt/hyper mice with increased levels of endogenous 
GDNF, and more persistent in MEN2B mice with constitutively active Ret. As suggested above, 
Gdnfwt/KO phenotype may be influenced by compensatory changes induced by GDNF reduction. 
Indeed, increased extracellular dopamine levels and DAT activity in the striatum of Gdnfwt/KO mice 
have been reported (Airavaara et al., 2004; Littrell et al., 2012). We conclude that about two-fold 
increase in endogenous GDNF expression (Kumar et al., 2015) does not affect amphetamine 
addiction-related behavior. 
We have previously shown that TH levels and activity are robustly increased in dSTR of MEN2B 
mice (Mijatovic et al., 2008, 2007). Now we show that the striatal levels of TH are elevated to a 
similar extent and in a gene dose-dependent manner in both dorsal and ventral striatum in MEN2B 
mice. At the same time, the ratio of p31Ser TH to total TH remained unchanged, which suggests 
that GDNF/Ret signaling does not specifically increase TH phosphorylation at serine 31. This is in 
contrast with earlier work, where ectopic GDNF infusion to the rat striatum reduced total TH 
levels, but increased pSer31, 40 and 19 TH levels at a GDNF dose of 100 µg and specifically 
increased striatal levels of pSer31 TH at a lower dose of 30 µg (Salvatore et al., 2009a, 2004). In 
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addition, we have previously shown that increased endogenous GDNF and ectopic GDNF 
applications have fundamentally different effects on brain dopamine system function (Kumar et 
al., 2015). Therefore, the above findings are likely specific to ectopic, high-dose GDNF application 
and support the use of the genetic models in this study to examine the role of GDNF signaling in 
the addiction process closer to the physiological range of GDNF expression. 
5. Conclusions 
Overall, our results suggest that the effects of Ret signaling on stimulant addiction-related 
behaviors are directly related to its regulatory role in mesolimbic dopamine neuron function at the 
level of dopamine biosynthesis. Specifically, amphetamine CPP extinction in MEN2B mice is 
severely stalled, which correlates with increased TH expression and dopamine levels in vSTR. 
Further research is required to resolve whether this also applies to other types of addictive drugs 
and which cellular mechanisms are involved. It would also be interesting to study whether humans 
carrying the corresponding MEN2B mutation (Pappa and Alevizaki, 2016) also display alterations in 
addiction-related behaviors. This would further support the clinical relevance of GDNF signaling in 
human addiction and the potential vulnerability to drug craving and relapse.  
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Fig. 1. Enhanced amphetamine-induced locomotor activity and longer expression of place 
preference in MEN2B mice. 
(A) Locomotor activity was measured during the 30 minutes conditioning sessions after saline and 
amphetamine (2 mg/kg) injections that took place on alternating days. In MEN2B mice locomotor 
activity was unaltered after saline injections, but increased after amphetamine (repeated-
measures ANOVA, p<0.001). (B) Locomotor activity was measured during the 15 minutes 
habituation, preference test, extinction and reinstatement sessions. In MEN2B mice locomotor 
activity was increased only in the reinstatement session, where animals received small priming 
amphetamine injections (0.5 mg/kg) (Student’s t-test, p=0.043). The magnitude of amphetamine 
CPP before (C) and after (D) eight conditioning trials, in multiple extinction sessions (E-L), and in 
reinstatement (M) is shown for mice that had amphetamine paired with the holes (Grid-; white 
bars) or grid (Grid+; black bars) floor. There was a clear and similar preference shift to the 
compartment where amphetamine was administered in both groups (B). However, while in Wt 
mice this preference was gone already in the second extinction session (F), in M2B mice the 
preference magnitude only diminished over time and was still detectable in the extinction session 
12 (L). In the reinstatement session, where 0.5 mg/kg of amphetamine was administered, both 
groups showed again strong preference towards the amphetamine-paired compartment (M). N = 
13 and 19 mice for Wt and M2B, respectively. In the CPP experiments statistical comparisons were 
made between the Grid+ and Grid– subgroups within each genotype using Student’s t-test. The 
number of days after the preference test is marked in the upper right corner of each panel. Wt, 
wild-type; M2B, MEN2B; *p < 0.05; **p < 0.01 and ***p < 0.001. 
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Fig. 2. Unaltered amphetamine-induced locomotion and CPP in GDNF hypermorphic mice. 
(A) Locomotor activity was measured during the 30 minutes conditioning sessions after saline and 
amphetamine (2 mg/kg) injections that took place on alternating days. In Gdnfwt/hyper mice 
locomotor activity was not significantly changed after saline or amphetamine (repeated-measures 
ANOVA, p>0.05). (B) Locomotor activity was measured during the 15 minutes habituation, 
preference test, extinction and reinstatement sessions. There were no significant differences 
between the genotypes. The magnitude of amphetamine CPP before (C) and after (D) eight 
conditioning trials, in multiple extinction sessions (E-I), and in reinstatement (J) is shown for mice 
that had amphetamine paired with the holes (Grid-; white bars) or grid (Grid+; black bars) floor. 
There was a clear and similar preference shift to the compartment where amphetamine was 
administered in both groups (D). This preference was gone already in the first extinction session in 
both groups (E). There were no further changes until the 5th extinction session F-I). In the 
reinstatement session, where 0.5 mg/kg of amphetamine was administered, both groups similarly 
showed again strong preference towards the amphetamine-paired compartment (J). N = 20 and 18 
mice for Wt and Gdnfwt/hyper, respectively. In the CPP experiments statistical comparisons were 
made between the Grid+ and Grid– subgroups within each genotype using Student’s t-test. The 
number of days after the preference test is marked in the upper right corner of each panel. Wt, 
wild-type; Hyper, GDNF hypermorphic allele; *p < 0.05 and ***p < 0.001. 
Fig. 3. Increased levels of dopamine, its metabolites, TH and pSer31 TH in MEN2B dSTR and 
vSTR. 
There was an increase in the dSTR dopamine (ANOVA p<0.0001) (A) and DOPAC (ANOVA 
p<0.0001) (B) levels, while HVA levels were not significantly elevated (ANOVA p=0.0717) (C) in 
MEN2B mice. There was a similar increase in the dSTR TH (ANOVA p=0.0036) (D) and pSer31 TH 
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(ANOVA p=0.0010) (E) levels, while their ratio remained unaltered (ANOVA p=0.825) (F). In vSTR, 
dopamine (ANOVA p<0.0001) (G), DOPAC (ANOVA p<0.0001) (H) and also HVA (ANOVA p=0.0021) 
(I) levels were increased. Also TH (ANOVA p<0.0001) (J) and pSer31 TH (ANOVA p=0.0011) (K) 
levels were increased, while their ratio remained unchanged (ANOVA p=0.429) (L). N = 8, 9 and 7 
mice for Wt/Wt and Wt/M2B and M2B/M2B, respectively. Wt, wild-type; M2B, MEN2B; dSTR, 
dorsal striatum; vSTR, ventral striatum; DOPAC, dihydroxyphenylacetic acid; HVA homovanillic 
acid; TH, tyrosine hydroxylase; *p < 0.05; **p < 0.01 and ***p < 0.001 versus Wt/Wt; #p < 0.05 
and ##p < 0.01 versus Wt/M2B. 
Fig. 4. Levels of dopamine, its metabolites, TH and pSer31 TH in dSTR and vSTR of GDNF 
hypermorphic mice. 
There were no differences in the dSTR TH (t-test p=0.369) (A) and pSer31 TH (t-test p=0.381) (B) 
levels and also their ratio remained unaltered (t-test p=0.0873) (C). There was no difference in the 
vSTR levels of dopamine (t-test p=0.249) (D), DOPAC (t-test p=0.150) (E) and HVA (t-test p=0.534) 
(F) in Gdnfwt/hyper mice. Similarly, in vSTR, TH (t-test p= p=0.141) (G) and pSer31 TH (t-test p=0.349) 
(H) levels were unchanged, while their ratio was reduced in Wt/Hyper mice (t-test p=0.0175) (I). N 
= 11 and 8 mice for Wt/Wt and Wt/Hyper, respectively. Wt, wild-type; Hyper, GDNF hypermorphic 
allele; dSTR, dorsal striatum; vSTR, ventral striatum; TH, tyrosine hydroxylase, DOPAC, 
dihydroxyphenylacetic acid; HVA homovanillic acid; *p < 0.05 versus Wt/Wt. 
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Supplementary Figure 1-4 captions 
 
Supplementary Figure captions 
Supplementary Figure 1. Enhanced amphetamine-induced locomotor activity and longer 
expression of place preference in Wt/M2B mice. 
The magnitude of amphetamine CPP before (A) and after (B) eight conditioning trials, in multiple 
extinction sessions (C-J), and in reinstatement (K) is shown for mice that had amphetamine paired 
with the holes (Grid-; white bars) or grid (Grid+; black bars) floor. There was a clear and similar 
preference shift to the compartment where amphetamine was administered in both groups (B). 
However, while in Wt mice this preference was gone already in the second extinction session (D), 
in Wt/M2B mice it lasted until the extinction session 12 (J). In the reinstatement session, where 
0.5 mg/kg of amphetamine was administered, both groups showed again strong preference 
towards the amphetamine-paired compartment (K). N = 13 and 13 mice for Wt and Wt/M2B, 
respectively. Statistical comparisons were made between the Grid+ and Grid– subgroups within 
each genotype using Student’s t-test. The number of days after the preference test is marked in 
the upper right corner of each panel. Wt, wild-type; M2B, MEN2B; *p < 0.05; **p < 0.01 and ***p 
< 0.001. 
 
Supplementary Figure 2. Levels of dopamine and its metabolites in MEN2B PFC, SN and VTA. 
HPLC analysis of dopamine, DOPAC and HVA levels in the PFC (A–C), SN (D–F) and VTA (G–I) of 
MEN2B mice. In PFC dopamine (ANOVA p=0.853) (A) and HVA (ANOVA p=0.537) (C) levels were 
unchanged, but DOPAC (ANOVA p=0.0436) (B) levels were slightly elevated. In the SN dopamine 
(ANOVA p=0.0005) (D) and DOPAC (ANOVA p=0.0228) (E) levels were elevated, while HVA (ANOVA 
p=0.388) (F) levels remained unchanged. In VTA dopamine (ANOVA p<0.0001) (G) levels were 
increased, while DOPAC (ANOVA p=0.105) (H) and HVA (ANOVA p=0.300) (I) levels were unaltered. 
N = 8, 9 and 7 mice for Wt/Wt and Wt/M2B and M2B/M2B, respectively. Wt, wild-type; M2B, 
MEN2B; PFC, prefrontal cortex; SN, substantia nigra; VTA, ventral tegmental area; DOPAC, 
dihydroxyphenylacetic acid; HVA homovanillic acid; *p < 0.05 and ***p < 0.001 versus Wt/Wt; #p < 
0.05 versus Wt/M2B. 
Supplementary Figure 3. Levels of dopamine and its metabolites in PFC, SN and VTA of GDNF 
hypermorphic mice. 
HPLC analysis of dopamine, DOPAC and HVA levels in the PFC (A–C), SN (D–F) and VTA (G–I) of 
Gdnfwt/hyper mice. In PFC dopamine (t-test p=0.467) (A), DOPAC (t-test p=0.274) (B) and HVA (t-test 
p=0.280) (C) levels were unchanged. Similarly, in the SN dopamine (t-test p=0.076) (D), DOPAC (t-
test p=0.690) (E) and HVA (t-test p=0.748) (F) levels were unchanged. In VTA dopamine (t-test 
p=0.0269) (G) levels were increased in Gdnfwt/hyper mice, while DOPAC (t-test p=0.060) (H) and HVA 
(t-test p=0.467) (I) levels were unaltered. N = 11 and 8 mice for Wt/Wt and Wt/Hyper, respectively. 
Wt, wild-type; Hyper, GDNF hypermorphic allele; PFC, prefrontal cortex; SN, substantia nigra; VTA, 
ventral tegmental area; DOPAC, dihydroxyphenylacetic acid; HVA homovanillic acid; *p < 0.05 versus 
Wt/Wt. 
Supplementary Figure 4. Presentative Western blot bands for TH and pSer31 TH. 
(A) Presentative bands for TH Western blot analysis including the standard curves from the 
calibrated standards. (B) Presentative bands for pSer31 TH Western blot including the standard 
curves from the calibrated standards. Wt, wild-type; Hyper, GDNF hypermorphic allele; M2B, 
MEN2B; dSTR, dorsal striatum; vSTR, ventral striatum; TH, tyrosine hydroxylase. 



 
